


Soy allergy

ImmunoCAP™ Specific IgE tests

ThermoFisher
SCIENTIFIC

ImmunoCAP™
Whole Allergen

ImmunoCAP™
Allergen Components












Good to know!



Up to 10% of all patients with birch sensitisation may also be at risk of reactions to soy, including risk of systemic reaction, especially when consuming less processed soy products.³

* Surrogate markers for profilin: Phl p 12, Bet v 2 or Pru p 4 ** No LTP referenced for soy in the WHO/IUIS

Soy (f14)	PR-10 Gly m 4 [#]	Storage proteins Gly m 5 / Gly m 6	Interpreting results*	Management considerations
			High risk of severe, systemic symptoms⁴⁻⁶ Primary soy allergy is likely. Potential high risk of severe systemic symptoms.	<ul style="list-style-type: none"> • Soy avoidance • Consider, in context of other risk factors, prescription of an adrenaline autoinjector
			Risk of local and systemic reactions^{3,7} Mainly local reaction, however high loads can lead to systemic reactions.	<ul style="list-style-type: none"> • Soy avoidance • Consider confirming the soy allergen load, especially if the patient is sensitised to Bet v 1. Check for possible consumption of unprocessed soy in drinks (soy milk) and dietary protein powders
			If all components of the algorithm are negative and f14 is positive, the patient could be sensitised to an untested allergen. ¹	

* Results should always be interpreted in the context of the clinical history * Gly m 4 content can be very low in soy extract-based tests. Therefore tests with Gly m 4 allergen component is recommended as supplement to testing with whole allergen.²

References: 1. Dramburg S, et al. *Pediatr Allergy Immunol* 2023;34(Suppl 28):e13854. 2. Kosma P, et al. *Acta Paediatr* 2011;100(2):305-306. 3. Mittag D, et al. *J Allergy Clin Immunol* 2004;113:148–154. 4. Holzhauser, T, et al. *J Allergy Clin Immunol* 2009;123(2):452-458. 5. Ito T, et al. *J Allergy Clin Immunol* 2010;125;2(Suppl 1):AB88. 6. Kleine-Tebbe, J. and Jakob, T. 2017. Editors: *Molecular Allergy Diagnostics*. Springer International Publishing Switzerland. 7. Ebisawa M, et al. *J Allergy Clin Immunol* 2013;132:976-978 e1-5.

Official product names: ImmunoCAP Allergen f14, Soybean; ImmunoCAP Allergen f431, Allergen component nGly m 5 beta-conglycinin, Soy; ImmunoCAP Allergen f432, Allergen component nGly m 6 Glycinin, Soy; ImmunoCAP Allergen f353, Allergen component rGly m 4 PR-10, Soy

 Learn more at thermofisher.com/allergencomponents

© 2025 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. Legal manufacturer: Phadia AB (a part of Thermo Fisher Scientific). 453351.AL.EU7.EN.V1.25